Valeo Pharma Inc.
VPHIF · OTC
7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.20 | 0.06 | -0.01 |
| FCF Yield | 8.80% | -76.53% | 4.98% | -56.27% |
| EV / EBITDA | -18.51 | -19.80 | -19.82 | -14.67 |
| Quality | ||||
| ROIC | -40.61% | -16.52% | -24.93% | -27.86% |
| Gross Margin | 27.25% | 19.44% | 15.53% | 4.82% |
| Cash Conversion Ratio | -0.06 | 0.45 | -0.21 | 0.29 |
| Growth | ||||
| Revenue 3-Year CAGR | 42.45% | 44.83% | 50.46% | 58.43% |
| Free Cash Flow Growth | 112.63% | -351.30% | 118.46% | -461.97% |
| Safety | ||||
| Net Debt / EBITDA | -17.11 | -18.40 | -13.19 | -11.85 |
| Interest Coverage | -0.83 | -1.01 | -1.28 | -1.90 |
| Efficiency | ||||
| Inventory Turnover | 1.86 | 1.72 | 1.18 | 1.22 |
| Cash Conversion Cycle | -16.47 | 19.31 | 33.36 | 89.20 |